|
|
Mohamad A. Hussein, MD
Leader, Multiple Myeloma Clinical Research
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida
Cost Effectiveness of Pegylated liposomal doxorubicin DOXIL®/CAELYX®)vs. doxorubicin in the VAd regimen (DVd) to treat multiple myeloma
|
|
|
06.14.04 |
|
Pegylated liposomal doxorubicin (DOXIL®/CAELYX®)was used in place of doxorubicin in the VAd regimen (DVd) to treat multiple myeloma. This study evaluates the cost effectiveness (CE) of these 2 regimens.
|
 related articles
|
|
back
print